-
New regulations for long prescriptions!
Time of Update: 2021-08-28
Long-term prescription management practices (Trial) Chapter I General Provisions Article 1 In order to standardize long-term prescription management, promote hierarchical diagnosis and treatment, promote rational drug use, and ensure medical quality and safety, in accordance with the "Practicing Physician Law", "Drug Administration Law", "Medical Institution Management Regulations", "Narcotic Drugs and Psychotropic Drugs Management Regulations" "Prescription Management Measures", "Regulations on Pharmaceutical Affairs of Medical Institutions" and other relevant regulations, formulate this specification .
-
A list of 17 groups of products will be announced soon
Time of Update: 2021-08-28
In order to further expand the scale of centralized procurement, and take advantage of the linkage between volume and price of centralized drug procurement, and volume-for-price, other provinces (cities) are now cordially invited to participate in the formation of a provincial cross-regional alliance to carry out centralized procurement of Chinese patent medicines .
-
Shanxi and Sichuan provinces publicly solicit opinions on the implementation rules for post-marketing drug changes
Time of Update: 2021-08-28
On August 12, the Shanxi Provincial Drug Administration released its opinions on the "Implementation Rules for the Administration of Post-Market Modification Recording (Trial)" (Draft for Solicitation
-
The National Talks on the Five Limits of Anticancer Drugs is here!
Time of Update: 2021-08-28
Participating patients purchase nationally negotiated anticancer drugs at designated retail pharmacies with prescriptions, and enjoy medical insurance benefits in accordance with the relevant provisions of the city’s outpatient clinics for specific diseases .
-
How to overcome the difficulties in the industry when the signal of centralized procurement of Chinese patent medicines is transmitted?
Time of Update: 2021-08-28
" On the basis of this, we adhere to the principle of giving priority to quality, being clinically demand-oriented, starting with high-priced and large-volume varieties, and scientifically and steadily advancing the reform of centralized procurement of proprietary Chinese medicines and formula granules .
-
Shi Yunzhong, director of Huaheng Biotechnology, resigns, nominates the candidate Mao Jianwen and is appointed as deputy general manager
Time of Update: 2021-08-28
Shi Yunzhong applied for resignation from the position of director of the third board of directors of the company due to personal work reasons .
-
Azivudin, who is in the hands of Roche, talks about the need to circumvent patents in drug development
Time of Update: 2021-08-28
Its structure is shown in the figure below:On November 13, 2007 (at this time, the patent of azvudine compound at Zhengzhou University has not yet been published, and the publication time is May 14, 2008), Roche researchers published the following article in the Journal of Biological Chemistry,This article published the structure and activity data of Azivudine (RO-0622), which is quite amazing.
-
Baiyunshan's executive deputy general manager Wu Changhai and deputy general manager Zhang Chunbo resigned
Time of Update: 2021-08-28
On the evening of August 16, Baiyunshan issued an announcement stating that the company’s board of directors had received written resignation reports from Executive Deputy General Manager Wu Changhai and Deputy General Manager Zhang Chunbo .
-
The world's third BTK-PROTAC starts clinical trial
Time of Update: 2021-08-28
Article source: Medical Rubik's Cube InfoAuthor: Shi BeiOn August 16, BeiGene registered the US Phase I study of BTK protein degradation agent (BTK-PROTAC) BGB-16673 on the American Clinical Network to treat B-cell malignancies.
-
Sartan drugs have been recalled on a large scale due to potential carcinogens!
Time of Update: 2021-08-28
Health Canada reminds patients that the recall of some products may affect the supply of medicines. Patients should be treated according to the doctor's advice. Unless the doctor recommends stopping
-
Deck Pharmaceuticals and Shanghai Pharmaceutical Holdings reached a cooperation on the commercialization of Celiniso
Time of Update: 2021-08-28
discussed the import authorization, distribution business, supply chain service and innovation of Celiniso (the special English trade name approved by the US FDA: XPOVIO®, the English common name: selinexor) in China Value-added and other levels reached cooperation intentions and signed agreements .
-
Heji Pharmaceutical's first ITK inhibitor application IND accepted in the clinical stage in the world
Time of Update: 2021-08-28
On August 17, Heji Pharmaceuticals revealed that its first clinical trial application for the oral ITK inhibitor CPI-818, which entered the clinical development stage, was accepted by the NMPA Drug Approval Center, and it was intended to be used for relapsed/refractory T cells.
-
Sihuan Pharmaceutical's Class 1 new drug CDK4/6 inhibitor approved for Phase III clinical treatment of breast cancer
Time of Update: 2021-08-28
It is also the malignant tumor with the highest incidence of women in the world, and about 680,000 patients died of breast cancer .
-
FDA grants emergency use authorization for the third dose of enhanced vaccination of two mRNA new crown vaccines
Time of Update: 2021-08-28
According to the data recently released by Moderna, the results of the phase 2 clinical trial testing the effect of the third dose of the enhanced vaccine showed that the level of neutralizing antibodies against the wild-type new coronavirus remained at 6 months after the second dose of vaccine.
-
Yunnan Provincial Food and Drug Administration issued a plan for the promotion of processing Chinese medicinal materials at the origin
Time of Update: 2021-08-28
(4) Based on the idea of fully implementing the main responsibility for quality of pharmaceutical manufacturers, standardize the behavior of Chinese herbal medicine manufacturers in our province to purchase Chinese herbal medicines from the origin (cutting them while they are fresh), including how to extend the quality management system, the demonstration text of the procurement contract and the quality agreement , Regarding how to review the production area processing enterprises, etc.
-
Nuocheng Jianhua's new TYK2 inhibitor ICP-332 completes the first subject administration
Time of Update: 2021-08-28
ICP-332 is a class 1 innovative drug with global independent intellectual property rights of Nuocheng Jianhua, and it is a new type of oral TYK2 inhibitor .
-
New medicine for atopic dermatitis!
Time of Update: 2021-08-28
AbbVie recently announced the evaluation of the oral JAK1 inhibitor Rinvoq (upadacitinib, upatinib) and the subcutaneous injection preparation Dupixent (Chinese trade name: dabital, generic name: dupilumab) The results of the head-to-head Phase 3b Heads Up study (NCT03738397) in adult patients with moderate to severe atopic dermatitis (AD) have been published in the international medical journal "JAMA Dermatology" .
-
Allogene's multiple myeloma therapy ALLO-715 won the FDA rare disease drug title
Time of Update: 2021-08-28
ALLO-715 is a CAR-T therapy targeting B cell maturation antigen (BCMA) and a potential new therapy for the treatment of multiple myeloma and other BCMA-positive malignancies .
-
Hengrui Medicine HRS2300 tablets were approved for clinical use
Time of Update: 2021-08-28
On August 16, Hengrui Pharmaceuticals issued an announcement stating that the company had recently received the approval of the National Medical Products Administration for the "Drug Clinical Trial Approval Notice" for HRS 2300 tablets, and clinical trials will be launched in the near future .
At present, no similar drugs have been approved globally, and there is no relevant sales data .
-
JiMu Biological Suprachoroidal Cavity Injection Therapy Obtains Exclusive Rights and Interests in Ten ASEAN Countries and India
Time of Update: 2021-08-28
On August 15th, JiMu Biotech announced that it has reached a license supplementary agreement with its partner Clearside Biomedical, Inc. (hereinafter referred to as “Clearside”), regarding its core p
